
News|Articles|June 27, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of June 27, 2022
Author(s)Sydney Jennings
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Advertisement
How many fully vaccinated Americans have received a booster dose?
According to the Centers for Disease Control and Prevention (CDC) as of today, June 27, 2022, at 3:38 PM, EDT:
47.2% of fully vaccinated persons in the US have received a booster dose of COVID-19 vaccine.
What percentage of people across age groups in the US have been fully vaccinated?
• 66.8% of total US population
• 71% of US population aged ≥5 years
• 75.3% of US population aged ≥12 years
• 76.8% of US population aged ≥18 years
• 91.3% of US population aged ≥65 years
How many cases of COVID-19 have been confirmed in the US?
According to the Johns Hopkins COVID-19 interactive map , as of today, June 27, 2022 at 4:20 PM, EDT, there have been:
• 87 048 889 confirmed cases and
• 1 016 145 deaths
• 591 331 125 total vaccine doses administered
• 1 016 145 deaths
• 591 331 125 total vaccine doses administered
In the past 28 days, the 3 states with the most new cases are:
1. California: 459 778
2. Florida: 305 467
3. Texas: 217 331
2. Florida: 305 467
3. Texas: 217 331
Deaths: California has the highest number of deaths due to COVID-19 with 92 114 reported fatalities, followed by Texas with 88 645 and Florida with 75 666.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 544 126 399 confirmed cases, 6 329 997 deaths, and 11 652 164 034 vaccine doses administered.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Novo Nordisk Files NDA for CagriSema, Novel GLP-1-amylin Combination for Chronic Weight Management
2
Zasocitinib Demonstrates Superiority vs Placebo and Apremilast in Phase 3 Plaque Psoriasis Trials
3
FDA Approves Lerodalcibep, Third-Generation PCSK9 Inhibitor, to Treat Hypercholesterolemia, Including HeFH
4
In CRC Screening, Progress Looks More Like Improved Follow-Through vs Next Breakthrough: Discussion with Mark Fendrick, MD
5

















































































































































































































































































